| Autor: |
Hartman JC; Pharmaceutical R&D Consulting, LLC, Loveland, Colorado., Del Rio CL; QTest Labs, LLC, Columbus, Ohio., Reardon JE; Revivo Therapeutics, Inc., Durham, North Carolina., Zhang K; Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan., Sabbah HN; Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan. |
| Jazyk: |
angličtina |
| Zdroj: |
JACC. Basic to translational science [JACC Basic Transl Sci] 2018 Nov 12; Vol. 3 (5), pp. 625-638. Date of Electronic Publication: 2018 Nov 12 (Print Publication: 2018). |
| DOI: |
10.1016/j.jacbts.2018.07.003 |
| Abstrakt: |
The effects of the nitroxyl donor BMS-986231 on hemodynamics, left ventricular (LV) function, and pro-arrhythmic potential were assessed using canine heart failure models. BMS-986231 significantly (p < 0.05) increased LV end-systolic elastance, pre-load-recruitable stroke work, ejection fraction, stroke volume, cardiac output, ratio of early-to-late filling time integrals, and early mitral valve inflow velocity deceleration time. BMS-986231 significantly decreased LV filling pressures, end-diastolic stiffness, the time-constant of relaxation, end-diastolic wall stress, systemic vascular resistance, and myocardial oxygen consumption. BMS-986231 had little effect on heart rate and did not induce de novo arrhythmias. Thus, BMS-986231 has beneficial inotropic, lusitropic, and vasodilatory effects. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
